Compare Under Armour Inc Class A (UA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Zimmer Biomet Holdings Inc — how do they compare? Under Armour Inc Class A trades at $4.78 (market cap $2.07B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.2× Under Armour Inc Class A's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Under Armour Inc Class A for 18 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| UA | ZBH | |
|---|---|---|
Market Cap | $2.07B | $16.95B |
Volume | 2,680,141 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $103.98 |
52-Week Low | $3.96 | $79.58 |
Typical Hold Time | 18 Days | 89 Days |
Enterprise Value | $3.05B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.81, up 2.34% with a bullish technical signal despite mixed fundamentals. The company reported declining revenues ($5.16B in 2025, $4.9B in 2026) and negative net income margins (-9.99%), though recent quarterly earnings showed beats in Q4 2025 and Q2 2026. Analyst sentiment is divided with 39.71% buy ratings, while cash flow trends show significant outflows (-$362M net in 2025).
The outlook remains challenging with revenue declines and profitability concerns, but the stock's low P/S ratio (0.41) may attract value investors. Key risks include sustained negative cash flow, competitive pressures, and execution on turnaround strategies. Near-term performance hinges on Q3 2026 earnings and guidance updates.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
